Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Pt must sign a preconsent prior to enrolling, for tissue testing
Newly diagnosed and =3 months from surgical diagnosis.
Histological confirmation of anaplastic glioma (oligodendroglioma, mixed, or
astrocytoma [WHO grade III]), as determined by pre-registration central
pathology review, and tumor is also co-deleted for 1p and 19q. NOTE: Mixed
gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic
predominance, as long as the tumor is also co-deleted for 1p and 19q.